Peter A. Thompson's Net Worth
Estimate Recalculated Jan 4, 2025 01:02AM EST
Who is Peter A. Thompson
Peter A. Thompson does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Trubion Pharmaceuticals, Inc, PMV Pharmaceuticals, Inc., Mirati Therapeutics, Inc., ALPINE IMMUNE SCIENCES, INC., Janux Therapeutics, Inc., Edgewise Therapeutics, Inc., ProNAi Therapeutics Inc, Adaptimmune Therapeutics PLC, Prevail Therapeutics Inc., Synthorx, Inc., ARS Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc., Decibel Therapeutics, Inc., RESPONSE BIOMEDICAL CORP, Anthera Pharmaceuticals Inc, and Principia Biopharma Inc..
SEC CIK
Peter A. Thompson's CIK is 0001357522
Past Insider Trading and Trends
2007 was Peter A. Thompson's most active year for acquiring shares with 13 total transactions. Peter A. Thompson's most active month to acquire stocks was the month of May. 2016 was Peter A. Thompson's most active year for disposing of shares, totalling 7 transactions. Peter A. Thompson's most active month to dispose stocks was the month of April. 2007 saw Peter A. Thompson paying a total of $50,288.66 for 5,000 shares, this is the most they've acquired in one year. In 2020 Peter A. Thompson cashed out on 45,335 shares for a total of $2,562,626.00, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
